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regard reliable biomarkers of response, ideally to be used as 
early surrogate endpoints for assessing response are much 
needed. Our results suggest that as early as at a three weeks 
interval from RT and ipilimumab, peripheral blood markers 
predict for development of a clinical objective response to 
the combination. 
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The use of PET/CT has increased much in the last decade, 
from a purely diagnostic to a radiotherapy planning and 
therapy monitoring tool. For these new applications, the 
quantitative and objective exploitation of PET/CT datasets 
becomes crucial given the well-established limitations of 
visual and manual analysis. Within this context, the 
Radiomics approach which consists in extracting large amount 
of information from multimodal images relies on a complex 
pipeline: image pre-processing, tumor segmentation, image 
analysis for shape and heterogeneity features calculation, 
and machine learning for robust and reliable features 
selection, ranking and combination with respect to a clinical 
endpoint. Although the Radiomics approach has been 
extensively applied to CT imaging, its use for PET/CT is more 
recent and less mature. There are however already a large 
body of published works hinting at the potential value of 
textural features and other advanced image features 
extracted from PET/CT in numerous tumour types. However, 
many methodological issues and limitations specific to 
PET/CT image properties have been highlighted by recent 
studies, This presentation aims at presenting both the 
promises and potential of advanced PET/CT image textural 
features analysis to build prognostic and predictive models, 
as well as the numerous pitfalls to avoid in order to further 
advance research in that promising field. 
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In the era of tailored medicine, the field of radiation 
oncology aims at identifying patients likely to benefit from 
treatment intensification and of those suffering from 
undesired treatment-related side-effects. In the past, patient 
selection in oncology was merely based on, e.g., 
randomisation, immunohistochemical staining of tumour 
biopsies, on tumour size or stage, or even on preferences. 
The introduction and increased availability of high-
throughput techniques, such as genomics, metabolomics and 
Next Generation Sequencing, have revolutionised the field.  
In radiation oncology, high-quality anatomical and functional 
imaging is, besides physical examination, the pillar for 
target-volume delineation, planning and response 
assessment. Therefore, ‘radiomics’, referring to the 
comprehensive quantification of tumour phenotypes through 
extensive image features analyses, is a logical consequence. 
Pioneered by the publication of Aerts et al. [1], the field is 
rapidly evolving regarding techniques, tumour sites and 
imaging modalities assessed.  
In this presentation, the status of radiomics for radiotherapy 
individualisation will be highlighted and possible areas of 
future research activities outlined.  
References: [1] Aerts HJWL, Rios Valezques E, Leijenaar RTH, 
et al. Decoding tumour phenotype by noninvasive imaging 
using a quantitative radiomics approach. Nature 
Communications 5, Article number: 4006. 
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Purpose or Objective: Molecular profiling is considered 
standard of care for advanced non-small cell lung cancer 
(NSCLC) patients. Approximately 25% of adenocarcinoma 
patients has a KRAS mutation; 10-15% has an activating EGFR 
mutation where tyrosine kinase inhibitors (TKI) are approved 
for first line treatment. EGFR and KRAS mutations are 
mutually exclusive. Obtaining enough tissue for molecular 
analysis may be difficult. Therefore, in this study we 
investigated whether EGFR and KRAS mutations can be 
distinguished from wildtype patients based on features 
derived from standard CT imaging. 
 
Material and Methods: From a retrospective database of 
NSCLC patients included between 2004 and 2014, all EGFR-
mutated (EGFR+, only exon 19 deletions or exon 21 L858R) 
patients, the consecutive KRAS-mutated (KRAS+) and 
EGFR/KRAS wildtype (WT) patients were included. The CT-
scan at first diagnosis of NSCLC (i.e. before any treatment) 
with the primary tumor visible was used for radiomics feature 
extraction. The primary tumor was delineated using a 
GrowCut segmentation algorithm (3D Slicer) and manually 
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adapted if needed. 724 CT features were calculated using 
radiomics software. To test if features were different for 
EGFR+, KRAS+ or WT patients one way ANOVA (initially 
without correction for multiple testing) was performed using 
a 5% significance level. A pair-wise comparison (t-test) 
identified significantly different groups. 
 
Results: 51 EGFR+, 47 KRAS+ and 32 WT patients were 
included. 41 features were significantly different between 
EGFR+, KRAS+ and WT patients. One feature is a first order 
gray-level statistics feature (7% of feature subgroup total), 
two are gray-level co-occurrence matrix based (9%), two 
gray-level size-zone matrix based (18%), one Laplacian-of-
Gaussian transform based (0.5%) and 35 are wavelet 
transform based features (7%). Statistics for the significant 
features are shown in Table 1. One easy to interpret 
significantly different feature for EGFR+ compared to WT 
patients was the median Hounsfield Unit (HU). EGFR+ 
patients had a median HU which is on average 54±23 HU 
higher compared to WT patients, see Figure 1. KRAS+ 
patients did not have a significantly different median HU 
compared to EGFR+ or WT patients. 
 
 
 
 
Conclusion: We showed that there are differences in 
radiomic CT features between EGFR+, KRAS+ and WT NSCLC. 
The next step will be to externally validate (work in progress) 
a robust radiomic signature, based on standard CT imaging. 
Also this allows to monitor radiomic signature evolvement 
under treatment. 
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Hadron therapy is an advanced technique in the field of 
radiotherapy that makes use of charged particles such as 
protons and carbon ions. The inverted depth-dose profile and 
the sharp dose fall-off after the Bragg peak offered by 
charged particle beams allow for a more precise localization 
of the radiation dosage to the tumor as compared to the 
conventional used photons. As a consequence, the 
surrounding healthy tissue receives a much lower dose. 
Besides this ballistic advantage, the use of high-linear energy 
transfer (LET) carbon ion beams offers also a biological 
advantage, i.e. a higher relative biological effectiveness 
(RBE) as compared to conventional low-LET photon therapy.  
Carbon ion radiation is thus more effective in inducing DNA 
damage, cell cycle arrest and cell death, thereby accounting 
for highly lethal effects, even in tumors that are resistant to 
X-ray irradiation. 
The response of an irradiated cell depends on the dose, dose-
rate, radiation quality, the lapse between the radiation-
induced stress and the analysis, and the cell type. In this 
context, genome-wide studies can contribute in exploring 
differences in signaling pathways and to unravel 'high-LET-
specific' genes. Several studies within SCK•CEN and outside 
have already compared changes in gene expression induced 
by different radiation qualities. Overall, the number of 
differentially expressed genes as well as the magnitude of 
(dose-dependent) gene expression changes was found to be 
more pronounced after irradiation with particle beams.  
Currently, the Radiobiology Unit of SCK•CEN is deeply 
investigating the effect of low- and high-LET radiation on the 
gene expression of different cancer cell lines in vitro. Our 
results clearly demonstrate a dose-dependent downregulation 
in several genes involved in cell migration and motility after 
carbon ion irradiation. A higher number of genes as well as 
more pronounced changes in their expression levels were 
found after carbon ion irradiation compared to X-rays. 
Further research are currently investigating whether the 
observed molecular changes also influence the cellular 
'behavior' after irradiation in terms of cell migration and 
motility after irradiation, since these are prominent 
characteristics of cancer progression and metastasis. 
Assessing both the risks and advantages of high-LET 
irradiation can contribute to the study of the biological 
effect on the tumor and will lead to further acceptance and 
improvement of the clinical outcome of hadron therapy.  
Acknowledgements: This work is partly supported by the 
Federal Public Service in the context of the feasibility study 
‘Application of hadrontherapy in Belgium’, which is part of 
action 30 of the Belgian cancer plan. Carbon ion irradiation 
experiments (P911-H) were performed at the Grand 
Accélérateur National d'Ions Lourds (Caen, France). 
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Particle therapy as cancer treatment, with either protons or 
heavier ions, provide a more favourable dose distribution 
compared to x-rays. While the physical characteristics of 
particle radiation have been the aim of intense research, less 
focus has been on the actual biological responses particle 
irradiation gives rise to. Protons and high LET radiation have 
a higher radiobiological effect (RBE), but RBE is a complex 
quantity, depending on both biological and physical 
parameters. One of the central questions in particle therapy 
is whether the tumor and the normal tissue has a differential 
RBE due to the difference in α/β ratio. Most of the data to 
enlighten this is in vitro data, and there is very limited in 
